Noven Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$20.7M
Doctors Paid
771
Transactions
2,488
2024 Total
$337,132
Payment Breakdown by Category
Research$19.9M (96.1%)
Consulting$56,753 (0.3%)
Food & Beverage$46,375 (0.2%)
Travel$38,931 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $19.9M | 1,088 | 96.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $412,005 | 203 | 2.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $257,484 | 222 | 1.2% |
| Consulting Fee | $56,753 | 32 | 0.3% |
| Food and Beverage | $46,375 | 840 | 0.2% |
| Travel and Lodging | $38,931 | 103 | 0.2% |
Payments by Type
Research
$19.9M
1,088 transactions
General
$811,548
1,400 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, 6-WEEK, IN-PATIENT STUDY TO ASSESS EFFICACY AND SAFETY OF HP-3070 IN SUBJECTS DIAGNOSED WITH SCHIZOPHRENIA | $10.3M | 0 | 539 |
| A 4-WEEK, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HP-5000 IN SUBJECTS WITH OSTEOARTHRITIS OA OF THE KNEE. | $2.5M | 0 | 363 |
| A PHASE I STUDY TO ASSESS CUMULATIVE SKIN IRRITATION AND SENSITIZATION OF HP-3070 TRANSDERMALL PATCH IN HEALTHY ADULTS | $1.5M | 0 | 50 |
| A RANDOMIZED, EVALUATOR-BLINDED STUDY TO EVALUATE SKIN IRRITATION AND SENSITIZATION OF D-AMPHETAMINE TRANSDERMAL SYSTEM (D-ATS) IN HEALTHY ADULTS | $1.4M | 0 | 21 |
| A RANDOMIZED, SINGLE DOSE, THREE WAY CROSSOVER STUDY TO DETERMINE THE EFFECT OF EXTERNAL HEAT ON THE PHARMACOKINETICS OF ASENAPINE TRANSDERMAL PATCH HP-3070 AND TO EVALUATE THE RELATIVE EXPOSURE TO SAPHRIS SMG ASENAPINE SUBLINGUAL IN HEALTHY ADULT SUBJECTS | $1.1M | 0 | 7 |
| A RANDOMIZED, SINGLE-DOSE, MULTIPART CROSSOVER STUDY TO DETERMINE THE EFFECT OF EXTERNAL HEAT ON THE PHARMACOKINETICS OF D-AMPHETAMINE TRANSDERMAL SYSTEM D-ATS AND TO COMPARE THE PHARMACOKINETICS OF AMPHETAMINE DELIVERED BY D-ATS, ADDERALL XR AND VYVANSE IN HEALTHY ADULT SUBJECTS | $974,172 | 0 | 21 |
| A 4-WEEK, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HP-5000 IN SUBJECTS WITH OSTEOARTHRITIS (OA) OF THE KNEE. | $618,754 | 0 | 19 |
| A RANDOMIZED, EVALUATOR-BLINDED STUDY TO EVALUATE SKIN IRRITATION AND SENSITIZATION OF D-AMPHETAMINE TRANSDERMAL SYSTEM D-ATS IN HEALTHY ADULTS | $598,005 | 0 | 6 |
| A PHASE I, SINGLE-CENTER, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, TWO-WAY CROSSOVER STUDY TO ASSESS THE BIOEQUIVALENCE AND ADHESION OF HP-1050 TRANSDERMAL PATCH COMPARED TO XULANE FOR 7 DAYS IN HEALTHY ADULT FEMALES | $458,717 | 0 | 3 |
| AN INVESTIGATIONAL STUDY TO EVALUATE ADHESION OF HP-3070 IN ADULTS WITH SCHIZOPHRENIA | $345,062 | 0 | 2 |
| A 4-WEEK, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HP-5000 IN SUBJECTS WITH OSTEOARTHRITIS OA OF THE KNEE. | $73,230 | 19 | 51 |
| SUMMATIVE USABILITY TEST OF HP-3070 TRANSDERMAL PATCH | $48,605 | 0 | 2 |
| A RANDOMIZED, OPEN-LABEL STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF TWO FORMULATIONS OF LEVORPHANOL TRANSDERMAL SYSTEM COMPARED TO LEVORPHANOL TARTRATE 2 MG TABLETS IN HEALTHY VOLUNTEERS RECEIVING CONCOMITANT DOES OF NALTREXONE | $29,659 | 0 | 1 |
| A RANDOMIZED, SINGLE-DOSE, MULTIPART CROSSOVER STUDY TO DETERMINE THE EFFECT OF EXTERNAL HEAT ON THE PHARMACOKINETICS OF D-AMPHETAMINE TRANSDERMAL SYSTEM (D-ATS) AND TO COMPARE THE PHARMACOKINETICS OF AMPHETAMINE DELIVERED BY D-ATS, ADDERALL XR AND VYVANSE IN HEALTHY ADULT SUBJECTS | $13,336 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Gregory Mattingly, M.d, M.D | Psychiatry | Saint Charles, MO | $74,067 | $0 |
| Andrew Cutler, Md, MD | Psychiatry | Lakewood Ranch, FL | $55,213 | $0 |
| Dr. Gustavo Alva, M.d, M.D | Psychiatry | Orange, CA | $54,587 | $0 |
| Mr. Napoleon Higgins, M.d, M.D | Psychiatry | Friendswood, TX | $51,520 | $0 |
| Michelle Holloway, Md, MD | Child & Adolescent Psychiatry | Oklahoma City, OK | $39,976 | $0 |
| Dr. Birgit Amann, M.d, M.D | Child & Adolescent Psychiatry | Troy, MI | $37,627 | $0 |
| Dr. Leslie Citrome, Md, Mph, MD, MPH | Psychiatry | Pomona, NY | $34,125 | $0 |
| Dr. Richard Jackson, M.d, M.D | Psychiatry | Bloomfield Hills, MI | $33,868 | $0 |
| Dr. Joel Young, Md, MD | Psychiatry | Rochester Hills, MI | $33,455 | $0 |
| Ms. Jennifer Ganem, Ms, Aprn, MS, APRN | Psychiatric/Mental Health | Londonderry, NH | $29,901 | $0 |
| Dr. Ilan Melnick, M.d, M.D | Psychiatry | Coral Gables, FL | $29,300 | $0 |
| Unknown Provider | — | — | $26,856 | $0 |
| Rakesh Jain, Md, MD | Psychiatry | Lake Jackson, TX | $26,171 | $0 |
| Dr. Craig Chepke, M.d, M.D | Psychiatry | Huntersville, NC | $23,456 | $0 |
| Dr. Vadim Baram, Md, MD | Geriatric Psychiatry | Saint Louis, MO | $14,598 | $0 |
| Dr. Jonathan Meyer, M.d, M.D | Psychiatry | San Diego, CA | $13,276 | $0 |
| Henry Nasrallah, Md, MD | Psychiatry | Cincinnati, OH | $13,276 | $0 |
| Dr. Mark Shukhman, Md, MD | Psychiatry | Skokie, IL | $13,182 | $0 |
| Dr. David Scheiderer, M.d, M.D | Psychiatry | Roanoke, VA | $12,214 | $0 |
| Dr. Amy Holland, M.d, M.D | Psychiatry | Marietta, GA | $10,202 | $0 |
| Ramon Martinez, Md, MD | Psychiatry | Orlando, FL | $10,092 | $0 |
| Ryan Dammerman, Md, MD | Family Medicine | Lancaster, OH | $10,000 | $0 |
| Joel Holiner, M.d, M.D | Addiction Psychiatry | Dallas, TX | $9,930 | $0 |
| Zainab Contractor, Md, MD | Neurology | Cincinnati, OH | $9,857 | $0 |
| Ann Childress | Child & Adolescent Psychiatry | Las Vegas, NV | $9,753 | $0 |
About Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. has made $20.7M in payments to 771 healthcare providers, recorded across 2,488 transactions in the CMS Open Payments database. In 2024, the company paid $337,132. The top product by payment volume is Xelstrym ($495,976).
Payments were distributed across 54 medical specialties. The top specialty by payment amount is Psychiatry ($552,788 to 196 doctors).
Payment categories include: Food & Beverage ($46,375), Consulting ($56,753), Research ($19.9M), Travel & Lodging ($38,931).
Noven Pharmaceuticals, Inc. is associated with 2 products in the CMS Open Payments database.